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Abstract
Background
The accurate evaluation of favorable response to neoadjuvant chemotherapy (NCT) is criti-
cal to determine the extent of surgery. We investigated independent clinicopathological and
radiological predictors to discriminate no residual carcinoma (ypT0) from residual ductal
carcinoma in situ (ypTis) in breast cancer patients who received NCT.
Patients and Methods
Parameters of 117 patients attaining pathological complete response (CR) in the breast
after NCT between January 2010 and December 2013 were retrospectively evaluated by
univariate and multivariate analyses. All patients underwent mammography, ultrasound,
and magnetic resonance imaging (MRI) before and after NCT.
Results
There were 67 (57.3%) patients with ypT0. These patients were associated with hormone
receptor-negative status, human epidermal growth factor receptor-2 (HER2)-negative
tumors, and a higher likelihood of breast-conservation surgery. Baseline mammographic
and MRI presentation of the main lesion, absence of associated microcalcifications, shape,
posterior features, and absence of calcifications on ultrasound were significantly associated
with ypT0. CR in mammography, ultrasound, or MRI after NCT was also related to ypT0. By
multivariate analysis, independent predictors of ypT0 were the triple-negative subtype
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[Odds ratio (OR), 4.23; 95% confidence interval (CI), 1.11–16.09] and CR in MRI after NCT
(OR, 5.23; 95% CI, 1.53–17.85). Stratified analysis by breast cancer subtype demonstrated
that MRI well predicted ypT0 in all subtypes except the HER2-positive subtype. In particular,
of 40 triple-negative subtypes, 22 showed CR in MRI and 21 (95.5%) were ypT0 after NCT.
Conclusion
Among imaging modalities, breast MRI can potentially distinguish between ypT0 and ypTis
after NCT, especially in patients with triple-negative breast cancer. This information can
help clinicians evaluate tumor response to NCT and plan surgery for breast cancer patients
of all subtypes except for those with HER2-enriched tumors after NCT.
Introduction
Neoadjuvant chemotherapy (NCT) is now commonly considered for breast cancer patients
who are potential candidates for adjuvant chemotherapy and it has been reported to have simi-
lar oncologic outcomes to adjuvant chemotherapy [1]. In addition, NCT increases the chances
of successful breast-conservation surgery, facilitates tumor biology research, and most impor-
tantly, provides information about prognosis [1–3]. For these advantages to be of use in real
clinical practice, accurate evaluation of response during NCT and preoperative assessment of
residual tumor burden through imaging modalities are critical for planning the extent of sur-
gery and for predicting prognosis. Recently, a meta-analysis suggested that breast magnetic res-
onance imaging (MRI) showed good performance in predicting pathologic complete response
(pCR) after NCT [4].
Residual ductal carcinoma in situ (DCIS) components of breast cancer after NCT are con-
sidered as pCR; however, surgery is differently planned if these components are of no residual
invasive and in situ carcinoma (ypT0). Obtaining clear resection margins with accurate preop-
erative evaluation helps decrease operation time and reduces the chances of repeating surgery
or early local recurrence. Chen et al. [5] demonstrated that positive cavity margin was the only
independent predictor for local-regional failure in patients treated with NCT before breast-
conservation surgery according to univariate and multivariate analysis. Most clinicians usually
plan the extent of surgery to achieve negative resections based on radiological examinations
and clinicopathological parameters. However, it has not been established which parameters
should have higher priority in daily practice.
In our review of previous literatures, there was only one article that dealt with discriminat-
ing ypT0 from residual DCIS in the breast after NCT [6]. In that study, the dynamic contrast-
enhanced MRI was reported to show good performance for distinguishing between lesions
with or without residual DCIS in breast cancer patients who demonstrated no residual invasive
cancer after NCT [6]. However, the study sample was limited, including only 15 cases of resid-
ual in situ carcinoma. It is therefore difficult to generalize their results to other samples, or to
analyze clinicopathological factors such as breast cancer phenotype, Ki-67 levels, or the use of
human epidermal growth factor receptor-2 (HER2) targeted therapy [7,8]. Thus, more com-
prehensive studies are necessary to determine the potential of MRI alongside future analyses of
clinicopathological findings of breast cancer patients who receive NCT.
The aim of this study was to investigate independent clinicopathological and radiological char-
acteristics, including breast cancer subtypes, in order to discriminate between ypT0 and residual
DCIS alone (ypTis) on final pathology in breast cancer patients who responded well to NCT.
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Patients and Methods
Patient selection
A total of 163 patients who achieved pCR in the breast after receiving NCT and who subse-
quently underwent definitive surgery of the breast and axilla from January 2010 to December
2013 at the Severance Hospital of Yonsei University College of Medicine, Seoul, Republic of
Korea were retrospectively selected. All patients in the study cohort were histologically con-
firmed to have primary invasive breast carcinoma at initial presentation. After therapeutic sur-
gery, permanent pathologic findings of the breast for all patients were reported as no residual
invasive and in situ carcinoma (ypT0) or residual in situ carcinoma alone (ypTis), irrespective
of pathologic nodal stage (ypNany). Forty-six (28.2%) patients who did not undergo mammog-
raphy, ultrasound, and breast MRI both prior to and after NCT were excluded from analysis.
Therefore, 117 patients were finally included in our study.
NCT regimens were mainly composed of 4 cycles of anthracycline plus cyclophosphamide
(AC) followed by 4 cycles of docetaxel (T) every 3 weeks in 91 (77.8%) patients. Twelve
(10.3%) patients received AC followed by T plus TS-1. Of the remaining 14 (12.0%) patients, 8
were treated with 6 cycles of T plus carboplatinum with bevacizumab and 2 received paclitaxel
plus carboplatinum. Each patient went through one of four regimens: four cycles of AC, 6
cycles of TAC, T plus carboplatinum with trastzumab, or paclitaxel plus trastzumab. This
study was approved by the Institutional Review Board of Severance Hospital, Yonsei University
Health System, Seoul, Republic of Korea (IRB No. 4-2015-0247). The requirement for written
informed consent was waived and patient information was anonymized and de-identified prior
to analysis.
Clinicopathological characteristics
Clinicopathological information, including expression of the estrogen receptor (ER), progester-
one receptor (PR), HER2, and Ki-67, was obtained through reviews of medical records and
pathology reports. Tumors with1% nuclear-stained cells by immunohistochemistry of core
needle biopsy specimens prior to NCT were considered positive for hormone receptors (HRs)
according to the American Society of Clinical Oncology/College of American Pathologists
(ASCO/CAP) guidelines [9]. HER2 staining was scored as 0, 1+, 2+, or 3+ according to ASCO/
CAP guidelines [10]. In cases with HER2 2+ results, fluorescence in situ hybridization (FISH)
was performed using a PathVysionHER2 DNA Probe Kit (Vysis, Downers Grove, IL, USA)
and HER2 gene amplification was defined with a HER2 gene/chromosome 17 copy number
ratio2.0 according to ASCO/CAP guidelines [10]. HER2 was considered positive with immu-
nohistochemistry scores of 3+ or gene amplification by FISH. Ki-67 levels were scored by
counting the number of positively stained nuclei and were expressed as a percentage of total
tumor cells.
Breast cancer subtypes were categorized by HRs and HER2 expression as follows: HRs
+/HER2-, ER-positive or PR-positive, and HER2-negative; HRs+/HER2+, ER-positive or PR-
positive, and HER2-positive; HRs-/HER2+, ER-negative, PR-negative, and HER2-positive;
HRs-/HER2-, ER-negative, PR-negative, and HER2-negative, a subtype also known as triple-
negative breast cancer.
Interpretation and analysis of imaging study
A radiologist (MJK) with more than 10 years of experience specializing in breast imaging inter-
preted mammography, ultrasound, and MRI images before and after NCT while blinded to
clinicopathological information. Data on mammographic factors were collected by reviewing
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mammography before and after NCT and the mammographic factors reviewed were as follows.
For mammography before NCT, tumor size (the largest diameter on mammography), the
extent of the tumor [single and multiple: the presence of two of more tumor foci within a single
quadrant of the breast (multifocal) or within different quadrants of the same breast (multi-
centric)], the presentation pattern of the main lesion (mass alone, the presence of microcalcifi-
cations regardless of mass, and non-visualization on mammography), the presence of
associated microcalcifications for the main lesion, and other imaging characteristics of the
main lesion (shape, margin, and density) and breast parenchymal patterns classified with the
Breast Imaging Reporting and Data System (BI-RADS) by the American College of Radiology
were studied [11]. For mammography after NCT, the mammographic factors studied for the
presentation of the main lesion were as follows; complete response including cases undetected
on mammography before NCT and residual mass or microcalcifications.
Ultrasonographic factors were reviewed and categorized as follows: For ultrasound before
NCT, the tumor size was defined as the largest diameter on ultrasound and imaging findings of
the main lesion were classified with BI-RADS [11]. Complete response or residual disease after
NCT was also determined for ultrasound.
MRIs were reviewed before and after NCT and tumor size was defined as the largest diame-
ter on the second post-contrast subtracted image. Background parenchymal enhancement was
categorized into one of four levels (1. minimal, 2. mild, 3. moderate, and 4. marked). The type
of lesion presented, the shape of the main lesion, the margin, the internal enhancement pattern,
and the time-intensity curve (washout, plateau, and persistent) were assessed [11]. The time-
intensity curve was evaluated using an automated software program (CADstream, Merge
Healthcare, Chicago, IL, USA). The presence of intratumoral necrosis, fibrosis, perilesional
edema, and the signal intensity of the lesion were evaluated with T2-weighted images (T2WI).
Residual tumors were assessed on MRI after NCT. An enhancing area distinct from the back-
ground parenchymal enhancement was considered to indicate the presence of residual tumors.
The absence of a distinct enhancing area was considered to indicate complete response to
chemotherapy.
Statistical analyses
Differences between the groups according to clinicopathological parameters were evaluated
using the chi-square test. Fisher’s exact test was used when appropriate. The independent two
sample t-test was used to compare the means of continuous numerical data. The predictive
value of imaging modality for the detection of residual DCIS at the time before surgery was
analyzed by receiver operating characteristic (ROC) curve analysis with calculated area under
the ROC curve (AUC). A logistic regression analysis was used to investigate independent
parameters including breast cancer subtype associated with ypT0 after completion of NCT.
The Cochran-Mantel-Haenszel test was used in stratified analyses according to breast cancer
subtype to explore the relationships between MRI findings after NCT and ypT0. All statistical
tests were two-sided, and p-values<0.05 were considered statistically significant. The SPSS
software version 20.0 (IBM Inc., Armonk, NY, USA) was used for all analyses.
Results
Of 117 patients, 67 (57.3%) were ypT0 and 50 (42.7%) were ypTis after breast surgery. Mean
age at diagnosis was 49.4 ± 9.7 years for the entire study sample. Table 1 presents clinicopatho-
logical characteristics according to presence of residual disease. There were no differences in
clinical features, tumor burden at presentation, pathologic nodal status after NCT, histologic
grade, Ki-67 proliferative index at diagnosis, or regimens of NCT between the two groups.
MRI and Response to Neoadjuvant Chemotherapy
PLOS ONE | DOI:10.1371/journal.pone.0149347 February 11, 2016 4 / 15
Table 1. Clinicopathological findings of patients with ypT0 and ypTis in the breast after neoadjuvant chemotherapy.
Parameters ypT0 (n = 67, %) ypTis (n = 50, %) P-value
Age (year)
Mean ± SD 49.6 ± 10.4 49.1 ± 8.7 0.772a
40 13 (68.4) 6 (31.6) 0.283
>40 54 (55.1) 44 (44.9)
Menopause
Premenopause 35 (56.5) 27 (43.5) 0.850
Postmenopause 32 (58.2) 23 (41.8)
BMI (kg/m2)
<25 46 (57.5) 34 (42.5) 0.940
25 21 (56.8) 16 (43.2)
Clinical tumor stage at presentation
T1 26 (66.7) 13 (33.3) 0.340
T2 34 (53.1) 30 (46.9)
T3-4 7 (50.0) 7 (50.0)
Node status at presentation
Negative 9 (64.3) 5 (35.7) 0.571
Positive 58 (56.3) 45 (43.7)
Regimens of NCT
AC followed by T 49 (73.1) 42 (84.0) 0.070
AC followed by T+TS1 6 (9.0) 6 (12.0)
Others 12 (17.9) 2 (4.0)
Pathologic node status after NCT
ypN0 58 (60.4) 38 (39.6) 0.141
ypN1-3 9 (42.9) 12 (57.1)
Histologic grade
I/II 36 (56.2) 28 (43.8) 0.807
III 31 (58.5) 22 (41.5)
ER
Negative 43 (65.2) 23 (34.8) 0.050
Positive 24 (47.1) 27 (52.9)
PR
Negative 56 (62.2) 34 (37.8) 0.048
Positive 11 (40.7) 16 (59.3)
HER2
Negative 50 (68.5) 23 (31.5) 0.002
Positive 17 (38.6) 27 (61.4)
Breast cancer subtype
HRs+/HER2- 17 (51.5) 16 (48.5) 0.001
HRs+/HER2+ 7 (36.8) 12 (63.2)
HRs-/HER2+ 10 (40.0) 15 (60.0)
HRs-/HER2- 33 (82.5) 7 (17.5)
Ki-67 before NCT (n = 105)
15% 17 (45.9) 20 (54.1) 0.119
>15% 42 (61.8) 26 (38.2)
Surgery
Breast-conservation 46 (68.7) 21 (31.3) 0.004
(Continued)
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Patients with ypT0 were more likely to have ER-negative, PR-negative, and HER2-negative
tumors. Therefore, triple-negative breast cancer was significantly more common in the ypT0
group. Breast-conservation surgeries were more frequently performed in patients with ypT0.
Mammographic findings for patients with ypT0 and ypTis are compared in Table 2 and S1
Appendix. At initial presentation, the size, extent, shape, and margin of the main lesion, mam-
mographic parenchymal pattern, and density did not differ between patients with ypT0 and
ypTis. The baseline main tumor frequently presented as microcalcifications with or without
mass in the ypTis group. Associated microcalcifications were more frequent in patients with
ypTis. After completion of NCT, mammographic findings of patients with ypT0 were signifi-
cantly noted as either complete response or undetected.
Table 3 presents the ultrasound results for the ypT0 and ypTis group. Baseline sonographic
size, margin, orientation, and echogenicity did not differ between the ypT0 and ypTis group.
Round shape of the main lesion, posterior enhancement, and sonographic absence of calcifica-
tions were more frequently observed in patients with ypT0. After NCT, ultrasound findings of
patients attaining ypT0 showed a higher proportion of complete response.
MRI findings are shown in Table 4. Before NCT, the size, shape, and margin of the main
lesion, background parenchymal enhancement, internal enhancement, T2WI, presence of
necrosis, and peritumoral edema did not differ between the two groups. The main lesion of the
ypT0 group was more likely to present as a mass, but non-mass enhancement was more fre-
quent in the ypTis group. MRI findings for patients with ypT0 after NCT mostly indicated
complete response.
The sensitivity, specificity, and accuracy for the detection of residual DCIS at the time before
surgery was 88.0%, 38.8%, and 59.8% for mammography, respectively, 82.0%, 40.3%, and
58.1% for ultrasound, respectively, and 68.0%, 70.1%, and 62.9% for MRI, respectively. Fig 1
shows ROC curve analysis for detecting ypTis. AUC of mammography, ultrasound, and MRI
was 0.63 (95% confidence interval [CI], 0.53–0.73), 0.61 (95% CI, 0.51–0.71), and 0.69 (95%
CI, 0.59–0.79), respectively.
Multivariate logistic regression analyses were conducted to identify independent predictors
of ypT0 after completion of NCT (Table 5). The triple-negative subtype and complete response
in MRI after NCT were significant predictors of ypT0. There was no significant interaction
between breast cancer subtypes and MRI results in the multivariate model. Since breast cancer
subtypes and MRI findings after NCT were the most important predictors, we conducted strat-
ified analyses according to breast cancer subtype to explore the relationship between MRI find-
ings and residual tumor burden after NCT (Table 6). In all breast cancer subtypes except the
HER2-positive subtype, breast MRI well predicted ypT0 with statistical significance. In HRs
+/HER2- and HRs+/HER2+ tumors, approximately two-thirds of the patients with complete
response observed on MRI after NCT were determined to be ypT0 after surgery, with signifi-
cant difference. In particular, 22 of 40 patients with HRs-/HER2- tumors showed complete
response according to MRI after NCT and among these patients, 21 (95.5%) were ypT0.
Table 1. (Continued)
Parameters ypT0 (n = 67, %) ypTis (n = 50, %) P-value
Total mastectomy 21 (42.0) 29 (58.0)
SD, standard deviation; BMI, body mass index; NCT, neoadjuvant chemotherapy; AC, anthracycline plus cyclophosphamide; T, docetaxel; ER, estrogen
receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HRs, hormone receptors.
aIndependent samples t-test.
doi:10.1371/journal.pone.0149347.t001
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However, there were no significant differences in patients with HRs-/HER2+ tumors. During
the study period, only 2 patients were treated with trastuzumab in combination with chemo-
therapy since anti-HER2 targeted therapy for neoadjuvant treatment is not covered by the
Korean National Health Insurance. When these 2 cases were excluded, MRI findings after
NCT were not associated with residual disease in 23 HRs-/HER2+ tumors (p = 0.193, Fisher’s
exact test).
Table 2. Mammographic findings of patients with ypT0 and ypTis.
Parameters ypT0 (%) ypTis (%) P-value
Before NCT
Mean Size ± SD 29.4 ± 21.8 33.7 ± 21.0 0.287a
Extent
Single 46 (63.0) 27 (37.0) 0.105
Multiple 21 (47.7) 23 (52.3)
Parenchymal pattern
b 19 (65.5) 10 (34.5) 0.078b
c 41 (51.2) 39 (48.8)
d 7 (87.5) 1 (12.5)
Presentation of main lesion
Mass alone 48 (70.6) 20 (29.4) <0.001
Microcalciﬁcations ± mass 11 (28.9) 27 (71.1)
Undetected 8 (72.7) 3 (27.3)
Associated microcalciﬁcations
Present 15 (31.2) 33 (68.8) <0.001
Absent 52 (75.4) 17 (24.6)
Shape
Round or oval 38 (63.3) 22 (36.7) 0.252
Irregular 15 (57.7) 11 (42.3)
Undetected 14 (45.2) 17 (54.8)
Margin
Circumscribed 4 (100.0) 0 (0.0) 0.302b
Microlobulated 7 (58.3) 5 (41.7)
Spiculated 12 (57.1) 9 (42.9)
Indistinct 29 (63.0) 17 (37.0)
Obscured 1 (33.3) 2 (66.7)
Undetected 14 (45.2) 17 (54.8)
Density
High density 23 (65.7) 12 (34.3) 0.295
Equal density 29 (58.0) 21 (42.0)
Low density or undetected 15 (46.9) 17 (53.1)
After NCT
Complete response or undetected 26 (81.2) 6 (18.8) 0.003b
Residual microcalciﬁcations alone 3 (50.0) 3 (50.0)
Residual mass ± microcalciﬁcations 38 (48.1) 41 (51.9)
aIndependent samples t-test.
bFisher’s exact test.
doi:10.1371/journal.pone.0149347.t002
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Discussion
Recent pooled analyses of clinical trials of NCT indicate that achievement of pCR is associated
with improved survival among breast cancer patients [3]. However, the implications of these
findings are thought to vary among breast cancer subtypes [12]. Although several classifica-
tions have been suggested for pathologic response to NCT in the breast, pCR of the breast in
practice is defined as no residual carcinoma (ypT0) or no residual invasive tumor with DCIS
present (ypTis) [13,14]. The prognostic implications of pCR are somewhat controversial but in
general, there are no differences in survival between patients with ypT0 and patients with
ypT0/is when ypN0 is attained [3,12]. However, ypT0 and ypTis cannot be accurately distin-
guished before definitive surgery, and some tumors do not respond in uniform patterns to
NCT [15,16]. The major clinical advantage of NCT is an increased success rate of breast-con-
servation surgery, which can be applied to patients with favorable response to NCT who fulfill
Table 3. Ultrasound findings of patients with ypT0 and ypTis.
Parameters ypT0 (%) ypTis (%) P-value
Before NCT
Mean Size ± SD 29.9 ± 20.0 31.6 ± 18.5 0.641a
Shape
Oval 37 (58.7) 26 (41.3) 0.015
Round 11 (91.7) 1 (8.3)
Irregular 19 (45.2) 23 (54.8)
Margin
Circumscribed 5 (100.0) 0 (0.0) 0.166
Indistinct 23 (60.5) 15 (39.5)
Angular 9 (69.2) 4 (30.8)
Microlobulated 20 (51.3) 19 (48.7)
Spiculated 10 (45.5) 12 (54.5)
Orientation
Parallel 38 (50.7) 37 (49.3) 0.054
Non-parallel 29 (69.0) 13 (31.0)
Echogenicity
Hyper-echo 1 (33.3) 2 (66.7) 0.466b
Iso-echo 11 (68.8) 5 (31.2)
Hypo-echo 55 (56.1) 43 (43.9)
Posterior features
Enhancement 28 (71.8) 11 (28.2) 0.038
Shadowing 10 (40.0) 15 (60.0)
No posterior features 29 (54.7) 24 (45.3)
Calciﬁcation
Present 9 (28.1) 23 (71.9) <0.001
Absent 58 (68.2) 27 (31.8)
After NCT
Complete response 27 (75.0) 9 (25.0) 0.010
Residual disease 40 (49.4) 41 (50.6)
aIndependent samples t-test.
bFisher’s exact test.
doi:10.1371/journal.pone.0149347.t003
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the criteria for breast-conservation surgery. Therefore, monitoring response to NCT and evalu-
ating residual tumor extent before surgery are clinically important practices.
Mammography is clinically useful for evaluating the extent of malignant-appearing calcifi-
cations. Lesions with residual DCIS frequently show calcifications on pre-chemotherapy mam-
mograms [6], as observed in this study. When main lesions initially presented as
microcalcifications with or without masses or when associated microcalcifications were
Table 4. Magnetic resonance findings of patients with ypT0 and ypTis.
Parameters ypT0 (%) ypTis (%) P-value
Before NCT
Mean Size ± SD 30.5 ± 19.9 32.1 ± 17.4 0.656a
BPE
1 56 (60.2) 37 (39.8) 0.452b
2 8 (44.4) 10 (55.6)
3 3 (50.0) 3 (50.0)
Presentation of main lesion
Mass 59 (62.1) 36 (37.9) 0.028
Non-mass enhancement 8 (36.4) 14 (63.6)
Shape
Round 14 (60.9) 9 (39.1) 0.282
Oval 39 (61.9) 24 (38.1)
Irregular 14 (45.2) 17 (54.8)
Margin
Circumscribed 13 (65.0) 7 (35.0) 0.403b
Irregular 48 (53.9) 41 (46.1)
Spiculated 6 (75.0) 2 (25.0)
Internal enhancement
Heterogeneous 34 (50.0) 34 (50.0) 0.133
Homogeneous 26 (70.3) 11 (29.7)
Rim enhancement 7 (58.3) 5 (41.7)
Time-intensity curve
Washout 64 (95.5) 49 (98.0) 0.830
Plateau or persistent 3 (4.5) 1 (2.0)
T2WI
High 42 (58.3) 30 (41.7) 0.768
Iso or low 25 (55.6) 20 (44.4)
Presence of necrosis
No 58 (56.9) 44 (43.1) 0.819
Yes 9 (60.0) 6 (40.0)
Peritumoral edema
No 48 (57.1) 36 (42.9) 0.966
Yes 19 (57.6) 14 (42.4)
After NCT
Complete response 47 (74.6) 16 (25.4) <0.001
Residual disease 20 (37.0) 34 (63.0)
BPE, Background parenchymal enhancement; T2WI, T2-weighted image.
aIndependent samples t-test.
bFisher’s exact test.
doi:10.1371/journal.pone.0149347.t004
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detected, ypTis was more likely to be observed after NCT. However, calcifications are also
indicative of necrotic tumor cells in patients who have received NCT. Our results showed that
approximately half of all cases with residual masses or microcalcifications after completion of
NCT were identified as ypT0. This result is similar to previous studies which indicated that
remnant calcifications after NCT are not correlated with residual tumor burden [6,17,18].
Moreover, 33.3% of stable microcalcifications and 27.7% of newly developed or additional cal-
cifications after NCT turned out to be pCR at the time of surgery, while 100% of calcifications
in cases with increased mass showed residual malignancy [19]. In HER2-positive breast can-
cers, adjacent DCIS could be completely eradicated by NCT combined with trastuzumab [20].
Therefore, remnant calcifications on mammography after NCT should not be considered to
constitute evidence of residual DCIS. While practical guidelines indicate that findings of diffuse
suspicious or malignant-appearing microcalcifications absolutely contraindicate breast-con-
serving therapy [21], a comprehensive clinical and imaging analysis which considers breast
cancer subtypes and therapeutic regimens is necessary to plan surgery after completion of
NCT.
Recently, Lee et al. [22] summarized inaccuracies among current practical tools used to eval-
uate residual tumor volumes in response to NCT and demonstrated that two-dimensional and
three-dimensional ultrasound and breast MRI show similar performances for the estimation of
residual breast cancer volume and prediction of pCR. In a retrospective analysis of patients
enrolled in the GeparTrio trial, ultrasound showed a high sensitivity for predicting ypT0 and
ypN0 and modestly improved the prediction of pCR by patient characteristics, which was con-
cluded to be a potentially useful modality for early prediction of pCR, despite breast MRI not
being included in the study [23]. In addition, ultrasound provides clinical advantages over MRI
including lower complexity, easier accessibility, shorter procedure time, easier interpretation,
cheaper costs, and lack of the hazards associated with contrast agents [22,23]. In the present
Fig 1. Receiver operating characteristics (ROC) curve analysis for detecting ypTis. AUC, area under
the ROC curve; CI, confidence interval; MRI, magnetic resonance imaging.
doi:10.1371/journal.pone.0149347.g001
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study, univariate analyses demonstrated that round shape on baseline sonographic analyses,
posterior features, sonographic absence of calcification, and complete response after NCT were
associated with a higher possibility of ypT0. However, there was no significant effect observed
in multivariate analysis, and more studies are required to confirm the role of ultrasound in the
prediction of residual tumor burden after NCT. Some potential explanations could lie in the
fact that all cases included in our study showed pCR at the time of surgery, which means that
residual disease was determined by in situ components of permanent pathology. No imaging
modality other than mammography is currently accepted in the evaluation of DCIS. For exam-
ple, ultrasound has limited ability to detect microcalcifications due to technical issues [24].
Although there are several circumstances in which ultrasound may be beneficial in the
Table 5. Predictors of ypT0 in the breast after completion of NCT.
Parameters Odds ratio 95% CI P-value
Breast cancer subtype 0.098
HRs+/HER2- Ref
HRs+/HER2+ 0.70 0.16–3.00 0.633
HRs-/HER2+ 0.97 0.26–3.54 0.958
HRs-/HER2- 4.23 1.11–16.09 0.034
MMG presentation of the main lesion
Mass or undetected Ref
Microcalciﬁcations ± mass 0.29 0.03–2.51 0.263
MMG associated microcalciﬁcations
Absent Ref
Present 0.84 0.13–5.60 0.855
US shape 0.370
Irregular Ref
Oval 1.11 0.39–3.17 0.846
Round 5.83 0.49–69.80 0.164
US posterior features 0.543
No posterior features Ref
Shadowing 1.40 0.38–3.17 0.846
Enhancement 1.92 0.60–6.21 0.275
US calciﬁcation
No Ref
Yes 1.34 0.22–8.27 0.751
MRI presentation of the main lesion
Mass Ref
Non-mass enhancement 1.18 0.32–4.31 0.807
MMG after NCT
Residual disease Ref
Complete response 0.90 0.20–4.06 0.890
US after NCT
Residual disease Ref
Complete response 2.69 0.79–9.19 0.114
MRI after NCT
Residual disease Ref
Complete response 5.23 1.53–17.85 0.008
CI, conﬁdence interval; Ref, reference; MMG, mammography; US, ultrasound; MRI, magnetic resonance imaging.
doi:10.1371/journal.pone.0149347.t005
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evaluation of patients with DCIS, sonographic findings of DCIS are very subtle. Therefore,
even though ultrasound might help predict pCR based [23], its ability to differentiate ypT0
from ypTis needs to be investigated. In addition, interobserver variability is a well-known limi-
tation of ultrasound [24]. Examining the exact primary site can be difficult in cases with
markedly decreased tumor burden size due to the limited number of landmarks available for
ultrasound.
A meta-analysis of MRI in the prediction of pCR after NCT revealed a high specificity of
0.91 and a relatively low sensitivity of 0.63 [4]. However, the performance of MRI can be influ-
enced by pCR rates, Ki-67 index, and breast cancer subtype [4,8,25,26]. The accuracy of MRI
for predicting residual tumor size was greatest in patients with the triple-negative phenotype or
HER2-positive breast cancers, and a better correlation was noted in the triple-negative subtype
with higher Ki-67 levels [8,25,26]. In this study, the triple-negative breast cancer subtype and
complete response on MRI after NCT were independent predictors for discriminating ypT0
from ypTis. This is supported by previous study results which have shown that mass enhance-
ment is an imaging characteristic of triple-negative breast cancer and that associated DCIS is
rare in cases without non-mass enhancement [27]. However, Moon et al. [7] reported that the
use of HER2-targeted agents resulted in less accurate MRI in patients with HER2-positive
tumors. In the present study, although most patients with HER2-positive tumors did not
receive HER2-directed therapy, MRI after NCT showed poor performance for the prediction
of ypT0 in HRs-/HER2+ tumors. Breast cancer subtypes are associated with pCR rates after
NCT, and the incorporation of HER2-targeted agents into NCT significantly improved pCR
rates in HER2-positive breast cancers [2,12,28]. The relationship between biologic mechanisms
and MRI used to discriminate ypT0 from ypTis in HER2-positive tumors has yet to be
determined.
Potential limitations of the present study are that it was a retrospective analysis using a sin-
gle institution database, and that the interpretations of imaging modalities were performed by
a single radiologist (although the radiologist was blinded to clinicopathological information).
In addition, patients with non-pCR after NCT were not analyzed, and confirmative parameters
for the discrimination of ypT0 from ypTis or residual invasive carcinoma were not evaluated.
Nevertheless, our study has two major strengths. One is that more than 100 cases attaining
Table 6. MRI findings after NCT according to postoperative pathologic results stratified by breast cancer subtype.
MRI after NCT ypT0 ypTis P-value P-valuea
HRs+/HER2- (n = 33) <0.001
Complete response 13 (68.4) 6 (31.6) 0.024
Residual disease 4 (28.6) 10 (71.4)
HRs+/HER2+ (n = 19)
Complete response 6 (66.7) 3 (33.3) 0.020b
Residual disease 1 (10.0) 9 (90.0)
HRs-/HER2+ (n = 25)
Complete response 7 (53.8) 6 (46.2) 0.226b
Residual disease 3 (25.0) 9 (75.0)
HRs-/HER2- (n = 40)
Complete response 21 (95.5) 1 (4.5) 0.033b
Residual disease 12 (66.7) 6 (33.3)
aCochran-Mantel-Haenszel test.
bFisher’s exact test.
doi:10.1371/journal.pone.0149347.t006
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pCR in the breast after NCT were investigated and the other is that all patients underwent
mammography, ultrasound, and breast MRI prior to and after NCT. Therefore, we were able
to comprehensively analyze the impact of all three imaging modalities before and after NCT on
the prediction of pCR while considering clinicopathological factors including breast cancer
subtype. Our multivariate analyses suggest that MRI after NCT affects discrimination between
ypT0 and ypTis differently according to breast tumor phenotype. Of note, since the high false-
positive rate and the subsequently frequent overcall rate are weaknesses of MRI, further study
with a larger multicenter cohort is necessary to validate our results and to evaluate the clinical
benefits and risks of MRI.
In conclusion, we demonstrated that the triple-negative breast cancer subtype and complete
response in MRI after NCT are independent predictors of ypT0. Among imaging modalities,
breast MRI could be suggested as a modality that accurately discriminates between ypT0 and
ypTis after NCT, especially in patients with triple-negative breast cancer. However, statistically
low AUC value and relatively high false-positive rate of MRI given in the present study suggest
that our findings are not definitive and additional study should be conducted. Until finding out
more clinically relevant imaging modalities and appropriate patient selection criteria, this
information can be useful in the evaluation of tumor response to NCT and in the planning of
surgery for breast cancer patients of all subtypes except for HER2-positive tumors after NCT.
Supporting Information
S1 Appendix. The raw data of image review.
(PDF)
Author Contributions
Conceived and designed the experiments: SP MJK. Performed the experiments: MJK. Analyzed
the data: SP MJK. Contributed reagents/materials/analysis tools: SP JHY JS HSP HJMMJK
EKK SIK BWP. Wrote the paper: SP MJK. Proofread or rechecked the manuscript: SP JHY JS
HSP HJMMJK EKK SIK BWP.
References
1. Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, et al. International expert con-
sensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth
Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona,
Italy (2010). J Natl Cancer Inst Monogr. 2011; 2011: 147–151. doi: 10.1093/jncimonographs/lgr037
PMID: 22043063.
2. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recom-
mendations from an international consensus conference on the current status and future of neoadju-
vant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012; 19: 1508–1516. doi: 10.1245/
s10434-011-2108-2 PMID: 22193884.
3. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete
response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;
384: 164–172. doi: 10.1016/s0140-6736(13)62422-8 PMID: 24529560.
4. Yuan Y, Chen XS, Liu SY, Shen KW. Accuracy of MRI in prediction of pathologic complete remission in
breast cancer after preoperative therapy: a meta-analysis. AJR Am J Roentgenol. 2010; 195: 260–268.
doi: 10.2214/ajr.09.3908 PMID: 20566826.
5. Chen K, Jia W, Li S, He J, Zeng Y, Yang H, et al. Cavity margin status is an independent risk factor for
local-regional recurrence in breast cancer patients treated with neoadjuvant chemotherapy before
breast-conserving surgery. Am Surg. 2011; 77: 1700–1706. PMID: 22273234.
6. Choi HK, Cho N, MoonWK, Im SA, HanW, Noh DY. Magnetic resonance imaging evaluation of resid-
ual ductal carcinoma in situ following preoperative chemotherapy in breast cancer patients. Eur J
Radiol. 2012; 81: 737–743. doi: 10.1016/j.ejrad.2011.01.013 PMID: 21300498.
MRI and Response to Neoadjuvant Chemotherapy
PLOS ONE | DOI:10.1371/journal.pone.0149347 February 11, 2016 13 / 15
7. Moon HG, HanW, Ahn SK, Cho N, MoonWK, Im SA, et al. Breast cancer molecular phenotype and the
use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy.
Ann Surg. 2013; 257: 133–137. doi: 10.1097/SLA.0b013e3182686bd9 PMID: 22968080.
8. Kim MJ, Kim EK, Park S, Moon HJ, Kim SI, Park BW. Evaluation with 3.0-T MR imaging: predicting the
pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadju-
vant chemotherapy. Acta Radiol. 2015; 56: 1069–77. doi: 10.1177/0284185114548507 PMID:
25228161.
9. HammondME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clini-
cal Oncology/College Of American Pathologists guideline recommendations for immunohistochemical
testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28: 2784–2795.
doi: 10.1200/jco.2009.25.6529 PMID: 20404251; PubMed Central PMCID: PMCPmc2881855.
10. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for
human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncol-
ogy/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31: 3997–
4013. doi: 10.1200/jco.2013.50.9984 PMID: 24101045.
11. Mercado CL. BI-RADS update. Radiol Clin North Am. 2014; 52: 481–487. doi: 10.1016/j.rcl.2014.02.
008 PMID: 24792650.
12. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and
impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrin-
sic breast cancer subtypes. J Clin Oncol. 2012; 30: 1796–1804. doi: 10.1200/jco.2011.38.8595 PMID:
22508812.
13. Marchio C, Sapino A. The pathologic complete response open question in primary therapy. J Natl Can-
cer Inst Monogr. 2011; 2011: 86–90. doi: 10.1093/jncimonographs/lgr025 PMID: 22043049.
14. Gebreamlak EP, Tse GM, Niu Y. Progress in evaluation of pathologic response to neoadjuvant chemo-
therapy of breast cancer. Anticancer Agents Med Chem. 2013; 13: 222–226. PMID: 22934701.
15. Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, et al. Statement of the science
concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Can-
cer Institute conference. J Clin Oncol. 2008; 26: 791–797. doi: 10.1200/jco.2007.15.0326 PMID:
18258988.
16. Wang S, Zhang Y, Yang X, Fan L, Qi X, Chen Q, et al. Shrink pattern of breast cancer after neoadjuvant
chemotherapy and its correlation with clinical pathological factors. World J Surg Oncol. 2013; 11: 166.
doi: 10.1186/1477-7819-11-166 PMID: 23883300; PubMed Central PMCID: PMCPmc3728037.
17. Weiss A, Lee KC, Romero Y, Ward E, Kim Y, Ojeda-Fournier H, et al. Calcifications on mammogram do
not correlate with tumor size after neoadjuvant chemotherapy. Ann Surg Oncol. 2014; 21: 3310–3316.
doi: 10.1245/s10434-014-3914-0 PMID: 25056851.
18. Li JJ, Chen C, Gu Y, Di G, Wu J, Liu G, et al. The role of mammographic calcification in the neoadjuvant
therapy of breast cancer imaging evaluation. PLoS One. 2014; 9: e88853. doi: 10.1371/journal.pone.
0088853 PMID: 24523942; PubMed Central PMCID: PMCPmc3921249.
19. Adrada BE, Huo L, Lane DL, Arribas EM, Resetkova E, YangW. Histopathologic correlation of residual
mammographic microcalcifications after neoadjuvant chemotherapy for locally advanced breast can-
cer. Ann Surg Oncol. 2015; 22: 1111–1117. doi: 10.1245/s10434-014-4113-8 PMID: 25287438.
20. von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, et al. Responsiveness of
adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastu-
zumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer
Res Treat. 2012; 132: 863–870. doi: 10.1007/s10549-011-1621-0 PMID: 21667238.
21. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, et al. Breast cancer version
3.2014. J Natl Compr Canc Netw. 2014; 12: 542–590. PMID: 24717572.
22. Lee MC, Gonzalez SJ, Lin H, Zhao X, Kiluk JV, Laronga C, et al. Prospective trial of breast MRI versus
2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy. Ann Surg Oncol. 2015;
22: 2888–2894. doi: 10.1245/s10434-014-4357-3 PMID: 25589151.
23. Marinovich ML, Houssami N, Macaskill P, von Minckwitz G, Blohmer JU, Irwig L. Accuracy of ultra-
sound for predicting pathologic response during neoadjuvant therapy for breast cancer. Int J Cancer.
2015; 136: 2730–2737. doi: 10.1002/ijc.29323 PMID: 25387885.
24. Hooley RJ, Scoutt LM, Philpotts LE. Breast ultrasonography: state of the art. Radiology. 2013; 268:
642–659. doi: 10.1148/radiol.13121606 PMID: 23970509.
25. De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, et al. Magnetic resonance
imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment
for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013;
119: 1776–1783. doi: 10.1002/cncr.27995 PMID: 23436342; PubMed Central PMCID:
PMCPmc3939707.
MRI and Response to Neoadjuvant Chemotherapy
PLOS ONE | DOI:10.1371/journal.pone.0149347 February 11, 2016 14 / 15
26. Mukhtar RA, Yau C, Rosen M, Tandon VJ, Hylton N, Esserman LJ. Clinically meaningful tumor reduc-
tion rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB
150007/150012; ACRIN 6657). Ann Surg Oncol. 2013; 20: 3823–3830. doi: 10.1245/s10434-013-
3038-y PMID: 23780381; PubMed Central PMCID: PMCPmc3824937.
27. Trop I, LeBlanc SM, David J, Lalonde L, Tran-Thanh D, Labelle M, et al. Molecular classification of infil-
trating breast cancer: toward personalized therapy. Radiographics. 2014; 34: 1178–1195. doi: 10.1148/
rg.345130049 PMID: 25208275.
28. Brown-Glaberman U, Dayao Z, Royce M. HER2-targeted therapy for early-stage breast cancer: a com-
prehensive review. Oncology (Williston Park). 2014; 28: 281–289. PMID: 24839797.
MRI and Response to Neoadjuvant Chemotherapy
PLOS ONE | DOI:10.1371/journal.pone.0149347 February 11, 2016 15 / 15
